JP Morgan Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $29
Portfolio Pulse from richadhand@benzinga.com
JP Morgan analyst Julio Romero maintains a Neutral rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and raises the price target from $28 to $29.
August 07, 2023 | 3:18 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan maintains a Neutral rating on ACADIA Pharmaceuticals and raises the price target from $28 to $29.
The news directly pertains to ACADIA Pharmaceuticals. The raised price target indicates a slightly more positive outlook, but the maintained Neutral rating suggests that the stock is not expected to outperform the market in the short term. Therefore, the short term impact on the stock price is expected to be neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100